- Reactive antibodies can persist after a past infection has cleared.
- An RNA test determines whether the virus is detectable now.
- Timing and recent exposure can change how a clinician interprets results.
Inside this story 2 perspectives
A patient handed a laboratory slip with the word “reactive” beside hepatitis C antibodies has learned something important about their health. They still need an answer to a more immediate question. Is the virus present in their blood now? For World Hepatitis Day on 28 July, the World Health Organization’s Africa office called attention to barriers to testing and treatment. The gap between that first slip and a completed diagnosis illustrates how a barrier can arise even after someone reaches a clinic.
Hepatitis C is a bloodborne infection that affects the liver. People can live with it for years without obvious symptoms. A blood test for antibodies looks for the body’s response to contact with the virus. Some people clear the infection without treatment. Others receive treatment and are cured. Either group may continue to have antibodies, so a reactive screening result on its own cannot tell a clinician whether an infection is still active.
What the laboratory can do next
A test for hepatitis C RNA looks for genetic material from the virus. If the screening test is reactive and RNA is detected, the result indicates current infection and the person needs to be linked to care. If RNA is undetectable after a reactive antibody test, there is usually no current infection. Clinical circumstances matter, especially if there has been a recent exposure.
The US Centers for Disease Control and Prevention describes a practical way to arrange the two steps. A service can collect the necessary specimens during one visit and have the laboratory proceed to the RNA test when an antibody test is reactive. The term patients may hear is “reflex testing”. It describes what happens to the specimen. It does not imply that the second test is available automatically at every clinic in every country.
For someone taking time off work or paying for transport, the distinction is tangible. One service can promise to call when both answers are available. Another may need the person to return for a further blood draw. Asking which arrangement applies, how the clinic sends results and who can explain them can make the next step easier to navigate.
When timing changes the answer
The antibody response takes time to develop. The CDC says detectable antibodies usually take eight to eleven weeks after an acute infection. A clinician assessing a recent exposure may therefore need RNA testing even when an antibody screen is negative. A result interpreted without the date and circumstances of exposure can give a different impression from one discussed with a health professional who knows that history.
Confirmation matters because treatment can change the outcome. WHO says direct-acting antiviral medicines can cure more than 95% of people with hepatitis C, though access to diagnosis and medicines remains uneven. A screening campaign can count how many people gave blood. A more revealing measure for the person who gave it is whether they received a clear answer and, if needed, an appointment for care.



